Technology Bundle ID: TAB-2330

Protease Deficient Bacillus anthracis with Improved Recombinant Protein Yield Capabilities

Request More Info
Licensing Contact:

Wade W Green
wade.green@nih.gov
Phone: 301-761-7505

Primary Inventors: 
Andrei Pomerantsev (NIAID)
Co-Inventors: 
Stephen Leppla (NIAID)
Therapeutic Area: 
Infectious Disease
Development Status: 
  • Early-stage
  • In vitro data available
Institute or Center: 
NIAID

Species of Bacillus, such as Bacillus anthracis, Bacillus cereus, and Bacillus subtilis, are attractive microorganisms for recombinant protein production in view of their fast growth rate, high yield, and ability to secrete produced products directly into the medium. Bacillus anthracis is also attractive in view of its ability to produce anthrax toxin and ability to fold proteins correctly. This application claims a B. anthracis strain in which more than one secreted protease is inactivated by genetic modification. Such a protease-deficient B. anthracis has an improved ability to produce recombinant secreted proteins compared to other bacteria, particularly other Bacillus. Improvements include production of intact (i.e., mature full-length) proteins, often at high yield.

Applications:
  • Vaccine production
  • Recombinant protein production
  • B. anthracis vaccine production
Advantages:
  • Highly efficient production of recombinant proteins
  • Low cost production of recombinant proteins

Patents

PCT Application PCT/US2012/049321
Filed on 2012-08-02
US Application 61/514,384
Filed on 2011-08-02
US Application 61/521,617
Filed on 2011-08-09
US Pat 10,273,548

Issued 2019-04-30
US Pat 9,555,064

Issued 2017-01-31

Publications

Pomerantsev A, et al.
PMID 21827967

Updated

Oct 21, 2011

Data Source: 
tts